Jump to content

Minocycline Topicals for Rosacea


Recommended Posts

  • Root Admin

There has been at least three pharmaceutical companies researching and testing a topical minocycline foam or gel for rosacea. We await to see the results of these clinical trials and if these are effective and which one will be released first. It looks like Foamix, a subsidiary of Menlo Therapeutics, has announced Amzeeq (for acne) and Zilxi (for rosacea) as the front runners if you scroll past this post and go to post number five in this thread. We will continue to follow the other 'horses' in this race. 

foamix_logo.jpg.b7fe788391363851a7e3f0d3zilxi.png.648d89f1d21970bfb6af75e572886bamzeeq400.png

(1) FMX103 Topical Minocycline FoamFoamix Ltd

biopharmx.png.57cf68a03667e38a48ba57f675

(2) BPX-04 Minocycline Topical Gel 1%BioPharmX, Inc.

havione.png.ef67d02f6ce39fbda9782cac2d09

(3) HY-01 Minocycline Gel 3%, Hovione

 

Link to post
Share on other sites
  • 4 weeks later...
  • Root Admin

A paper published in the British Journal of Dermatology concluded that after treatment with 1% and 3% Minocycline Topical Gel, this resulted with a "significantly decreased inflammatory lesion counts and a significantly larger proportion of subjects achieved IGA success at week 12 in the 3% topical minocycline group. These findings support further evaluation of minocycline gel for the treatment of inflammatory lesions associated with papulopustular rosacea."

Metronidazole will be having some competition. 

Link to post
Share on other sites
  • 4 weeks later...
  • Root Admin

foamix_logo.jpg.b7fe788391363851a7e3f0d3zilxi.png.648d89f1d21970bfb6af75e572886b

Results of Two Phase 3, Randomized, Clinical Trials, FMX103 1.5%, conclusion: 

FMX103 1.5% was efficacious for moderate-to-severe papulopustular rosacea, while maintaining a favorable safety profile

The authors of the paper add this limitation, "The generalizability of these data from a controlled clinical trial should be examined in a real-world setting."

For more information

Link to post
Share on other sites
  • 1 month later...
  • Root Admin

"Webster et al. report a multicentre, randomized, double‐masked, parallel‐group, vehicle‐controlled study to evaluate the safety and efficacy of minocycline gel 1% and 3%. Topical minocycline had insignificant systemic absorption but produced significant reductions in mean inflammatory lesion counts with both the 1% and 3% concentrations. The response rate in the vehicle group was quite high, as is often the case in diseases with fluctuating inflammation. However, the 3% concentration of minocycline showed a significantly greater proportion of patients achieving Investigator's Global Assessment success at week 12 compared with vehicle. A topical minocycline foam formulation is in development, and this may provide a further useful option for treating papulopustular rosacea. How topical minocycline compares with other topical rosacea treatments is as yet unclear."

Br J Dermatol. 2020 Mar 18;:
Expanding treatment options for rosacea.
Hampton PJ

Link to post
Share on other sites
  • 2 months later...
  • Root Admin

menlo_logo.png

Menlo Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ZILXI™ (minocycline) topical foam, 1.5%, for the treatment of inflammatory lesions of rosacea in adults. ZILXI, developed as FMX103 by Menlo’s wholly-owned subsidiary Foamix Pharmaceuticals Ltd. (“Foamix”), is the first minocycline product of any kind to be approved by the FDA for use in rosacea. Official Announcement

zilxi.pngfoamix_logo.jpg.b7fe788391363851a7e3f0d3

Zilzi is a tetracycline that has done well in clinical trials. You will need to ask your physician for a prescription. 

Product Insert

 

Link to post
Share on other sites
  • 1 month later...
  • 1 month later...
  • Admin pinned this topic
  • 1 month later...
  • Root Admin

"Overall, the current study demonstrates that topical minocycline gel is safe, efficacious and well tolerated in patients with papulopustular rosacea. The findings of this study support further evaluation of topical minocycline gel for the treatment of papulopustular rosacea."

Br J Dermatol. 2020 Sep; 183(3): 471–479. With Photos
A multicentre, randomized, double‐masked, parallel group, vehicle‐controlled phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea
G. Webster, Z.D. Draelos,  E. Graber,  M.S. Lee,  S. Dhawan,  M. Salman,  and G.N. Magrath

Link to post
Share on other sites
  • Root Admin

zilxi-rosacea-canister.pngvynetheraputics.jpg
Now available announced by Vyne Therapeutics. Ask your dermatologist. Post your experience in this thread. Find the reply button. 

"The Company also announced that the annual list price of ZILXI will be $485 per 30-gram canister, in parity with the wholesale price of AMZEEQ® (minocycline) topical foam, 4%, the Company's topical minocycline indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older." 
PR Newswire Association LLC. All Rights Reserved. A Cision company

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...